Tempus AI’s ALERT study demonstrates that resistance to change in cardiology can be overcome—transforming data into a powerful, scalable tool for saving lives

Tempus Trial: From Concept to Clinical Validation

The recent trial marks a pivotal moment for Tempus, shifting its core proposition from theoretical potential to proven, real-world application. Unlike a small-scale pilot, this study stands as the largest multicenter, cluster-randomized trial to date focused on an automated EHR-based system for valvular heart disease. Conducted across 35 hospitals and involving 2,016 echocardiograms, the trial robustly tested Tempus’s ability to seamlessly integrate into clinical settings and prompt actionable care.

This research directly addresses a longstanding challenge in cardiology: clinical inertia. For patients with untreated, symptomatic severe aortic stenosis, the two-year mortality rate nears 50%. Such a high risk highlights the urgent need for timely intervention—a gap Tempus’s AI is designed to close. The study specifically evaluated whether automated, AI-powered alerts could prompt faster assessments and treatments for these patients.

Validation at the American College of Cardiology’s 75th Annual Scientific Session & Expo brought significant attention and credibility. Presenting these results to a leading audience in the field underscores the technology’s promise. The findings were compelling: automated notifications resulted in a 40% relative increase in life-saving valve procedures and a 27% rise in multidisciplinary heart team evaluations within 90 days. This is more than a statistical improvement—it demonstrates AI’s capacity to overcome clinical inertia and standardize patient care.

For Tempus, the trial confirms the strength of its infrastructure. The Tempus Next platform has shown it can accurately extract vital information from complex reports and deliver actionable, guideline-based recommendations directly to clinicians. This success accelerates the path toward widespread clinical adoption, shifting the conversation from “can AI help?” to “how quickly can we scale this proven approach?” The trial offers a clear roadmap for closing care gaps and transforming Tempus’s data-driven vision into a scalable solution for better patient outcomes.

From Clinical Validation to Commercial Expansion

While clinical validation is a major milestone, its true significance lies in how it accelerates Tempus’s ability to monetize its underlying infrastructure. Years of building a vast, secure data ecosystem have positioned the company for exponential growth.

Tempus’s data moat is defined by both its scale and security. The company has established secure data pipelines with over 4,500 U.S. hospitals, creating a proprietary channel for real-world clinical data that powers AI development. The trial’s success in cardiology demonstrates the infrastructure’s effectiveness in a critical specialty and highlights its potential to expand into other fields, such as oncology and neurology, proving the model’s scalability.

The efficiency gains are remarkable. Tempus’s AI-driven data abstraction can process massive datasets in days—work that would have taken human teams months. In a recent pilot, AI processed 60,000 patient records in just a few days, a task that previously required months of manual effort. This shift not only accelerates data readiness but also transforms Tempus’s 38 million research records and 7 billion clinical notes into valuable, analysis-ready assets, creating a high-margin product.

This is where the financial engine ignites. Data licensing, already a high-margin business, is growing rapidly, with Insights revenue up 69.5% year-over-year. The trial provides a compelling, real-world example that can be leveraged to further expand this revenue stream. Life sciences companies increasingly rely on validated, real-world data like Tempus’s to design better trials and refine patient targeting. The cardiology results strengthen Tempus’s value proposition across all therapeutic areas, making its multimodal dataset even more attractive.

Ultimately, this creates a positive feedback loop. Clinical validation reduces risk for new hospital partners, expanding the data moat. More data, processed efficiently by AI, leads to additional high-margin licensing deals. The resulting revenue supports further AI innovation and infrastructure growth. The trial is the catalyst that proves the infrastructure’s value—now Tempus is poised to scale, turning a single clinical achievement into a long-term growth engine.

Financial Overview: Balancing Rapid Growth with Profitability and Debt

Tempus’s financial narrative is one of rapid expansion, but also significant challenges on the road to sustainable profitability, especially given its considerable debt. This creates a delicate balance for investors to monitor.

Growth is robust. In the fourth quarter, Tempus’s revenue soared 83.0% year-over-year to $367.2 million, driven by diagnostics (up 121.6%) and data licensing (up 69.5%). The company is building a strong network effect, as shown by a Net Revenue Retention of 126% and over $1.1 billion in remaining contract value. For a business betting on widespread AI adoption in healthcare, this type of scaling is crucial.

However, this rapid growth comes at a cost. The Data & Other segment, which includes high-margin data licensing, saw its gross margin drop to 69.7% in Q3 from 76.8% a year earlier. This margin compression, despite soaring revenue, reflects the heavy investments needed to maintain infrastructure, advance AI capabilities, and secure new hospital partnerships. While common for companies building foundational infrastructure, it highlights that the journey to high profitability is still underway.

The balance sheet adds further complexity. Tempus closed the quarter with $518.8 million in debt, offset by $759.7 million in cash and marketable securities. While this net cash position offers some security, the debt introduces financial leverage and interest expenses that will impact future earnings. The company’s guidance for about $65 million in Adjusted EBITDA for 2026 signals a focus on profitability, but achieving this will require careful management of margin pressures and debt obligations.

In summary, Tempus faces a tug-of-war between validating its AI infrastructure at scale and the financial demands of rapid expansion. The company must continue to accelerate revenue and data monetization to offset margin erosion and debt costs, all while navigating the risks inherent in a high-growth, pre-profitability environment. The coming quarters will be critical in determining whether Tempus can achieve this balance.

Key Drivers and Risks: Charting the Course for Widespread Adoption

While the roadmap from clinical validation to widespread adoption is now clearer, it is marked by both significant opportunities and notable risks. The next steps will test Tempus’s ability to turn its cardiology breakthrough into a broad, revenue-generating platform, while also managing the challenges that come with rapid scaling.

• Immediate Catalysts: Securing reimbursement for the xM test is essential for monetizing Tempus’s advanced liquid biopsy offerings. Without insurance coverage, the high cost of these tests limits their adoption and price growth. Additionally, increasing average selling prices for liquid biopsy and diagnostic tests will directly improve margins as volumes grow.
• Scalability: The next challenge is replicating the cardiology success in other high-value disease areas. Tempus is already preparing for this, with AI-focused sessions at major research conferences on patient matching and identification in oncology trials. The expansion of these AI-driven trials and subsequent data licensing agreements will be key indicators of the platform’s broader utility.
• Risks: Margin pressure remains a significant concern, as seen in the recent decline to 69.7% in the Data & Other segment. Heavy investment in infrastructure and AI must eventually translate into improved profitability. There is also execution risk in expanding AI applications beyond cardiology, as each new area requires fresh clinical validation and regulatory approval. Finally, the company’s $518.8 million debt load increases financial risk, especially if growth slows.

Key metrics to watch include the adoption rate of the Tempus Next platform by health systems following the cardiology trial. Rapid expansion into other specialties would indicate strong network effects. Quarterly updates on data licensing growth will also reveal whether this high-margin revenue stream is accelerating as planned.

Strategy Spotlight: Absolute Momentum Long-Only Approach

• Entry Criteria: Initiate a long position in TEM when the 252-day rate of change is positive and the closing price is above the 200-day simple moving average (SMA).
• Exit Criteria: Close the position if the price falls below the 200-day SMA, after 20 trading days, or if a take-profit (+8%) or stop-loss (−4%) threshold is reached.
• Risk Controls: Take-profit set at 8%, stop-loss at 4%, and a maximum holding period of 20 days.

Backtest Performance

• Total Return: 5.37%
• Annualized Return: 7.12%
• Maximum Drawdown: 37.61%
• Profit-Loss Ratio: 1.75
• Total Trades: 24
• Winning Trades: 9
• Losing Trades: 15
• Win Rate: 37.5%
• Average Hold Period: 4.54 days
• Max Consecutive Losses: 4
• Average Gain per Win: 11.16%
• Average Loss per Loss: 5.75%
• Largest Single Gain: 16.97%
• Largest Single Loss: 8.28%

In conclusion, Tempus’s investment case depends on its ability to navigate both the opportunities and risks ahead. The recent trial has provided the spark; the challenge now is to drive adoption across the healthcare landscape while managing the financial and operational complexities that come with rapid growth.